India's food safety regulator has opened three adjudication cases against Nestlé India over its infant nutrition products, including a follow-up formula whose sample failed the prescribed biotin requirement not once but twice, in laboratory testing, and again on re-analysis at a referral laboratory.
 

The Food Safety and Standards Authority of India (FSSAI) announced the action on September 18, following scrutiny of the products and their promotional material on e-commerce platforms. Two of the three cases concern marketing. For NAN Excella Pro Stage 1, the regulator flagged claims relating to "5 HMOs" and "Whey Protein". For Lactogen Pro 1, it questioned a claim describing the whey protein as "easy to digest". Such promotional claims, FSSAI said, are contrary to provisions governing foods for infant nutrition, including the bar on material intended to increase the saleability of infant foods. It also cited the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992.